Using the fully humanized mesothelin CAR with reduced immunogenicity, iCasM28z CAR, Adusumilli and his colleagues conducted two phase I clinical trials with intrapleural administration (NCT02414269) for malignant pleural mesothelioma (MPM) and with systemic administration (NCT02792114) for triple negative breast cancer, respectively. Here, MSLN is linked to triple-negative breast carcinoma.